NR 546 Week 3 Exam V1 | NR 546
Advanced Pharmacology
Psychopharmacology for the PMHNP |
Actual Q&A with Rationale (NR546 Week 3
Exam) | Chamberlain University
1. Which neurotransmitter is primarily implicated in the reward system and is associated with
the ‘positive’ symptoms of schizophrenia when levels are excessive in the mesolimbic
pathway?
A. Serotonin
B. Glutamate
C. GABA
D. Dopamine
Answer: D
Rationale: Dopamine is the central neurotransmitter involved in the brain’s reward and
pleasure centers. Excessive dopaminergic activity in the mesolimbic pathway is theorized
to cause hallucinations and delusions. Managing these levels is a primary focus of
antipsychotic pharmacotherapy.
2. When a drug acts as a partial agonist at a receptor, what is the expected biological
response compared to a full agonist?
A. A response that is less than the maximal response of a full agonist
,B. A complete lack of biological response
C. An equivalent response to a full agonist but with higher affinity
D. A response that is the exact opposite of a full agonist
Answer: A
Rationale: Partial agonists bind to the same receptor as full agonists but elicit only a sub-
maximal response. Even when all receptors are occupied, the intrinsic activity is lower than
that of a full agonist. This property allows partial agonists to act as either an agonist or an
antagonist depending on the level of endogenous ligand present.
3. The PMHNP understands that a medication with a high volume of distribution (Vd)
suggests which of the following characteristics?
A. The drug is primarily confined to the plasma compartment
B. The drug is highly protein-bound and cannot cross membranes
C. The drug is likely lipophilic and distributes widely into tissues
D. The drug is rapidly excreted by the kidneys through filtration
Answer: C
Rationale: A high volume of distribution indicates that the medication has distributed
extensively throughout the body’s tissues rather than remaining in the blood. Lipophilic
drugs typically exhibit this characteristic because they can easily cross lipid bilayers. This
, pharmacokinetic parameter helps determine the loading dose required to achieve a target
plasma concentration.
4. In the context of the CYP450 enzyme system, how does a ‘prodrug’ function differently
than a standard active drug?
A. A prodrug is active upon ingestion and is inactivated by the liver
B. A prodrug requires metabolic conversion to an active form to exert its effects
C. A prodrug bypasses the liver entirely and is metabolized by the kidneys
D. A prodrug is only used for topical applications and is not absorbed systemically
Answer: B
Rationale: Prodrugs are pharmacologically inactive compounds that must undergo
metabolic conversion, usually in the liver, to become active. This strategy is often used to
improve the drug’s absorption, distribution, or stability. For instance, lisdexamfetamine is a
prodrug that is converted to active dextroamphetamine in the blood.
5. Which dopamine pathway is associated with the development of extrapyramidal
symptoms (EPS) and tardive dyskinesia when dopamine receptors are blocked?
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway
Advanced Pharmacology
Psychopharmacology for the PMHNP |
Actual Q&A with Rationale (NR546 Week 3
Exam) | Chamberlain University
1. Which neurotransmitter is primarily implicated in the reward system and is associated with
the ‘positive’ symptoms of schizophrenia when levels are excessive in the mesolimbic
pathway?
A. Serotonin
B. Glutamate
C. GABA
D. Dopamine
Answer: D
Rationale: Dopamine is the central neurotransmitter involved in the brain’s reward and
pleasure centers. Excessive dopaminergic activity in the mesolimbic pathway is theorized
to cause hallucinations and delusions. Managing these levels is a primary focus of
antipsychotic pharmacotherapy.
2. When a drug acts as a partial agonist at a receptor, what is the expected biological
response compared to a full agonist?
A. A response that is less than the maximal response of a full agonist
,B. A complete lack of biological response
C. An equivalent response to a full agonist but with higher affinity
D. A response that is the exact opposite of a full agonist
Answer: A
Rationale: Partial agonists bind to the same receptor as full agonists but elicit only a sub-
maximal response. Even when all receptors are occupied, the intrinsic activity is lower than
that of a full agonist. This property allows partial agonists to act as either an agonist or an
antagonist depending on the level of endogenous ligand present.
3. The PMHNP understands that a medication with a high volume of distribution (Vd)
suggests which of the following characteristics?
A. The drug is primarily confined to the plasma compartment
B. The drug is highly protein-bound and cannot cross membranes
C. The drug is likely lipophilic and distributes widely into tissues
D. The drug is rapidly excreted by the kidneys through filtration
Answer: C
Rationale: A high volume of distribution indicates that the medication has distributed
extensively throughout the body’s tissues rather than remaining in the blood. Lipophilic
drugs typically exhibit this characteristic because they can easily cross lipid bilayers. This
, pharmacokinetic parameter helps determine the loading dose required to achieve a target
plasma concentration.
4. In the context of the CYP450 enzyme system, how does a ‘prodrug’ function differently
than a standard active drug?
A. A prodrug is active upon ingestion and is inactivated by the liver
B. A prodrug requires metabolic conversion to an active form to exert its effects
C. A prodrug bypasses the liver entirely and is metabolized by the kidneys
D. A prodrug is only used for topical applications and is not absorbed systemically
Answer: B
Rationale: Prodrugs are pharmacologically inactive compounds that must undergo
metabolic conversion, usually in the liver, to become active. This strategy is often used to
improve the drug’s absorption, distribution, or stability. For instance, lisdexamfetamine is a
prodrug that is converted to active dextroamphetamine in the blood.
5. Which dopamine pathway is associated with the development of extrapyramidal
symptoms (EPS) and tardive dyskinesia when dopamine receptors are blocked?
A. Mesocortical pathway
B. Nigrostriatal pathway
C. Mesolimbic pathway
D. Tuberoinfundibular pathway
